#vaping #VALI Vaping-Associated Lung Injury is real. If you have friends or family who use these, beware they are not without harm.

I really don’t see the downside of moving treatment to the neoadjuvant setting. Yes it’s going to be very difficult to show a survival difference but we know neoadj and adj chemotherapy are equivalent (except that more people get it in the neoadj), and it’s hard to imagine there

This study raises several critical questions. Rather than focusing solely on subsequent treatments, we should investigate whether patients with poor-prognosis, early-relapsing disease require distinct initial treatment strategies. The study included only early-relapsing patients.

Everyday I see how a diagnosis of cancer completely upends the lives of people and families. For patients and families: The progress to cure and control cancer is proceeding at an amazing pace. It’s truly remarkable with the new targeted therapies and immunotherapy options. Be

📢 On June 3, 2025, Darolutamide received its FDA approval for de novo metastatic castration-sensitive prostate cancer (mCSPC). To mark this milestone, we created this comprehensive infographic: ✅ All modern AR pathway inhibitors now approved for mCSPC 📉 10-year FDA timeline

Vincent Rajkumar Mayo Myeloma While many #CART centers are proficient in managing CRS & ICANS, we are all learning how best to evaluate & manage emerging late toxicities in the field. Fortunate to have ANASTASIA ZEKERIDOU and Navreet Chowla, MD, FACG bring their team expertise. Stay tuned for updates as we learn more.

Just out! New IMS/ IMWG Definition of High Risk Myeloma. Journal of Clinical Oncology #IMWG25 Myeloma Society International Myeloma Foundation Nikhil C. Munshi, MD marivi mateos Sagar Lonial MD Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 Noopur Raje

We're probably all guilty of delaying a doctor’s appointment at least once in our lives—but Early Detection = Better Outcomes. This #MensHealthMonth, learn what symptoms you shouldn't ignore. Don’t wait. Talk to your doctor.

Multiple positive trials, one common feature: advancing the use of ADCs to earlier lines of treatment. It’s happening fast, and it is producing meaningful clinical benefits. Yet, questions remain. Thank you ESMO - Eur. Oncology for this interview!

Dr Ajai Chari shares the USCF guidelines for prevention and management of infections post BCMA BsAb and CAR T cells #mmsm #EHA2025 #EHA25

Just out: Mayo Clinic mSMART Risk Stratification of Myeloma #EHA25 1/ We recommend and use same high risk cytogenetic definition as the latest IMS/IMWG paper 2/ Primary plasma cell leukemia is high risk myeloma 3/ We define Double-hit high risk myeloma msmart.org/mm-treatment-g…

🎉🚨 Hot off the press! Congrats to JCO Oncology Practice on their 20th anniversary! With #ASCO25 ASCO behind us, perfectly timed for #EHA2025 👉 Delighted to share our Policy & Practice paper on "Imperative of Comprehensive Molecular Profiling as Standard of Care for Patients With Rare

🫁 Summary of immunotherapies early stage NSCLC 1/3 ⭐️ Key clinical data as of June 2025 ※ #ASCO25 data included.

🔥 Just out in Journal of the @NCCN — mentoring Suriya Baskar on this project (and others) has been one of the most fulfilling experiences of my career 🙌 We take on a rare care delivery topic relevant to the care of patients with #NeuroendocrineTumors 📊 What we found in >7,000 inpatient

Pembrolizumab now FDA Oncology approved in resectable LA-HNSCC based off KEYNOTE-689: - mEFS: 51.8 vs 30.4 most (HR: 0.73) - Benefit greater with CPS ≥10 (HR 0.66) - 2yr EFS: 75% vs 62% #OncTwitter #MedTwitter OncoAlert #ASCO25 #AACR25

🎉Finally out🎉 Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma Now in Blood Journals Portfolio Timely for #EHA2025🥰 #mmsm ashpublications.org/blood/article/…

Dr Kai Rejeski gives a helpful guide to predicting post car T haematotoxicity (ICAHT) #EHA2025 #EHA25 #lymsm

These are important data and should change practice for LGL leukemia. Oncology Brothers

Want to change the world? Prioritize fatherhood. Children with fathers in their homes are 4X less likely to live in poverty. Children with involved fathers are 33% less likely to repeat a grade. 71% of high school dropouts come from fatherless homes. 85% of youth in

🚨 Wow! Sunday morning brings an incredible trifecta - 2 NEJM papers + 1 The Lancet Haematology study dropping simultaneously with #EHA2025! 🩸📚 ⚡️ OncoAlert 1/3 Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic Leukemia NEJM nejm.org/doi/full/10.10…